Intellia Therapeutics
NTLA50
$12.18arrow_drop_up0.99%$0.11
NTLA50
$12.18
arrow_drop_up0.99%Performance History
| Key Stats | |
|---|---|
| Open | $11.94 |
| Prev. Close | $12.08 |
| EPS | -5.45 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 11.85 | 12.42 |
| 52 Week Range | 11.79 | 34.87 |
| Ratios | |
|---|---|
| EPS | -5.45 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Intellia Therapeutics (NTLA)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. John M. Leonard M.D.
- Headquarters
- Cambridge
- Employees
- 598
- Exchange
- NASDAQ
Keep an eye on Intellia Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Intellia Therapeutics 's (NTLA) price per share?
The current price per share for Intellia Therapeutics (NTLA) is $12.18. The stock has seen a price change of $0.12 recently, indicating a 0.99% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Intellia Therapeutics (NTLA)?
For Intellia Therapeutics (NTLA), the 52-week high is $34.87, which is 186.29% from the current price. The 52-week low is $11.79, the current price is 3.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Intellia Therapeutics (NTLA) a growth stock?
Intellia Therapeutics (NTLA) has shown an average price growth of -4.38% over the past three years. It has received a score of 2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intellia Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Intellia Therapeutics (NTLA) stock price performance year to date (YTD)?
As of the latest data, Intellia Therapeutics (NTLA) has a year-to-date price change of -60.48%. Over the past month, the stock has experienced a price change of -11.74%. Over the last three months, the change has been -43.24%. Over the past six months, the figure is -49.71%. Looking at a longer horizon, the five-year price change stands at -23.01%.
help
Is Intellia Therapeutics (NTLA) a profitable company?
Intellia Therapeutics (NTLA) has a net income of -$481.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.26% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.59K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $36.28M, although specific revenue growth data is currently not available. The gross profit is $27.3M. Operating income is noted at -$515.29M. Furthermore, the EBITDA is -$527.52M.
help
What is the market capitalization of Intellia Therapeutics (NTLA)?
Intellia Therapeutics (NTLA) has a market capitalization of $1.24B. The average daily trading volume is 12.23, indicating the stock's liquidity and investor engagement.